Pregabalin Capsule
Product Images NDC 80425-0129

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph depicting the percent of patients improved against percent improvement in pain from baseline for Pregabalin dosed at 200 mg, 110 mg, and 25 mg three times a day, compared to a placebo group. The x-axis shows percent improvement in pain ranging from 0 to 100, and the y-axis shows the percent of patients improved, also from 0 to 100.*

FDA Label Image

Fig 10

A line graph comparing the estimated percentage of subjects without LTR (loss to remission or response) over 180 days between Pregabalin and Placebo groups. The x-axis represents days, and the y-axis represents the estimated percentage of subjects without LTR. Two lines indicate Pregabalin and Placebo results over time.*

FDA Label Image

Fig 11

A line graph depicting the percent of subjects improved from baseline to Week 12 based on BOCF, comparing Pregabalin and Placebo groups. The y-axis shows the percent of subjects improved, ranging from 0 to 100%, while the x-axis shows the percent improvement from baseline, with distinct vertical markers at 30, 50, and 70 percent improvement.*

FDA Label Image

Fig 12

A line graph comparing the percentage of subjects improved from baseline to week 16 BOCF for Pregabalin 300 mg capsules versus placebo. The x-axis represents percent improvement, while the y-axis shows percent of subjects improved, with Pregabalin displayed as a solid line and placebo as a dashed line.*

FDA Label Image

Fig 2

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. Two lines represent Pregabalin 100 mg three times a day and placebo, illustrating patient response rates at various improvement thresholds.*

FDA Label Image

Fig 3

Line graph depicting the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and a placebo group. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig 4

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing differences in pain improvement outcomes.*

FDA Label Image

Fig 5

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares three groups: pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo, illustrating patient response rates to different dosages versus placebo over a range of improvement percentages.*

FDA Label Image

Fig 6

A bar chart comparing responder rates (%) across different dosages of Pregabalin capsules (50 mg/day to 600 mg/day) versus placebo in two studies (E1 and E3). Dosages are shown with administration frequency (BID or TID). The chart indicates statistically significant responder rates with certain dosages versus placebo, with sample sizes (N) beneath each bar.*

FDA Label Image

Fig 7

A line graph depicting seizure reduction as median percent change from baseline relative to varying doses of pregabalin (mg/day). The graph compares four studies: Study E1 BID, Study E2 TID, and Studies E3 BID and TID. Dose ranges from 0 (placebo) to 600 mg/day on the x-axis; seizure reduction percentage ranges from 0 to 60 on the y-axis. Significant p-values (≤ 0.0001 or 0.0007) are indicated by each data point.*

FDA Label Image

Fig 9

A line graph showing the percentage of patients improved on the vertical axis against the percent improvement in pain from baseline on the horizontal axis. The graph compares Pregabalin daily doses of 300 mg, 450 mg, and 600 mg, as well as a placebo. Lines represent each dose and placebo, illustrating trends in patient improvement.*

FDA Label Image

Formula

This image shows the formula for calculating Creatinine Clearance (CLCr), which includes age, weight, serum creatinine levels, and a factor of 0.85 for female patients. It is a text panel presenting this calculation method as part of the drug information.*

FDA Label Image

Pregabalin 300mg Cap Qty 90 Ndc 80425 0129

Label for Pregabalin 300 mg capsules by Advanced Rx Pharmacy of Tennessee, LLC. Displays proprietary and generic name, strength, dosage form, and storage instructions (20°C to 25°C). Includes lot number, expiration date, source NDC, and a note to compare to Lyrica. Contains a barcode and caution about federal law restrictions on transfer.*

FDA Label Image

Structure

Chemical structure diagram of Pregabalin showing its molecular arrangement with amino, carboxyl, and hydrocarbon groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.